Vinci SA VCISY
30.35 USD -0.53 (-1.72%)
Nov 3, 2026, 3:45 PM EST
30.33 Day range 30.57
29.35 52-week range 42.10
- YTD
- -13.78%
- 1 year
- -8.39%
- Market cap
- 66.90B
- EPS (ttm)
- 2.63
- P/E ratio
- 11.54
- YTD return
- -13.78%
- 1-year return
- -8.39%
- Volume
- 19.73K
- Avg volume
- 342.63K
- Open
- 30.55
- Previous close
- 30.88
- Day's range
- 30.33 – 30.57
- 52-week range
- 29.35 – 42.10
2Y +2.61 (+9.41%)
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jul 29, 2026 | Jun 30, 2026 | 1.01 | 1.06 | +0.05 | +4.95% |
| Feb 5, 2026 | Dec 31, 2025 | 1.52 | 1.60 | +0.08 | +5.26% |
| Jul 30, 2025 | Jun 30, 2025 | 0.947 | 0.983 | +0.04 | +3.80% |
| Feb 6, 2025 | Dec 31, 2024 | 1.26 | 5.15 | +3.89 | +308.73% |
| Oct 24, 2024 | Jun 30, 2024 | 0.915 | 3.71 | +2.80 | +305.46% |
| Mar 15, 2024 | Dec 31, 2023 | 1.20 | 4.98 | +3.78 | +315.00% |
News
Vinci Compass to Buy AustralRe, Launching Permanent Capital Solutions 
VINCI COMPASS ANNOUNCES THE LAUNCH OF VINCI PERMANENT CAPITAL SOLUTIONS WITH THE ACQUISITION OF AUSTRALRE 
3 Wall Street Analysts See Intuitive Surgical Hitting $500. Here's the Bull Case. 
Vinci SA: Possible 10% FCFY On A Good Cash Cow Plus Electrification Growth Base 
Is Vinci (VCISY) Stock Undervalued Right Now? 
Vinci (OTCMKTS:VCISY) Sets New 12-Month Low – Should You Sell? 
New meta-analysis shows statistically significant improvements in patient outcomes associated with da Vinci surgery versus laparoscopic and open surgery across 13 common benign conditions 
Should Value Investors Buy Vinci (VCISY) Stock? 
Critical Contrast: Cadeler A/S (NYSE:CDLR) & Vinci (OTCMKTS:VCISY) 
Vinci Compass Investments Q2 Earnings Call Highlights
Your note
Sign in to keep a note on VCISY — it syncs with the Stock Master app.